vs
Side-by-side financial comparison of RENASANT CORP (RNST) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $273.8M, roughly 1.1× RENASANT CORP). RENASANT CORP runs the higher net margin — 32.2% vs 12.8%, a 19.4% gap on every dollar of revenue. Over the past eight quarters, RENASANT CORP's revenue compounded faster (29.3% CAGR vs 4.2%).
Renasant Bank is an American regional commercial financial institution based in Tupelo, Mississippi. The bank has more than 280 branches in Alabama, Florida, Georgia, Mississippi, Louisiana, Tennessee, North Carolina and South Carolina. Renasant Bank operates under the parent company Renasant Corporation and is affiliated with Renasant Nation, a platform through which they publish blogs and shows.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
RNST vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $273.8M | $295.9M |
| Net Profit | $88.2M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 32.2% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | 112.5% | 68.3% |
| EPS (diluted) | $0.94 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $273.8M | — | ||
| Q4 25 | $278.4M | $295.9M | ||
| Q3 25 | $269.5M | — | ||
| Q2 25 | $267.2M | $317.0M | ||
| Q1 25 | $170.7M | $316.2M | ||
| Q4 24 | $167.1M | $297.0M | ||
| Q3 24 | $220.3M | $289.5M | ||
| Q2 24 | $163.8M | $306.1M |
| Q1 26 | $88.2M | — | ||
| Q4 25 | $78.9M | $38.0M | ||
| Q3 25 | $59.8M | — | ||
| Q2 25 | $1.0M | $-17.7M | ||
| Q1 25 | $41.5M | $22.6M | ||
| Q4 24 | $44.7M | $34.9M | ||
| Q3 24 | $72.5M | $33.6M | ||
| Q2 24 | $38.8M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 34.8% | 18.4% | ||
| Q3 25 | 27.9% | — | ||
| Q2 25 | 1.0% | -7.5% | ||
| Q1 25 | 30.4% | 12.2% | ||
| Q4 24 | 29.8% | 16.0% | ||
| Q3 24 | 44.2% | 13.8% | ||
| Q2 24 | 29.6% | 15.0% |
| Q1 26 | 32.2% | — | ||
| Q4 25 | 28.4% | 12.8% | ||
| Q3 25 | 22.2% | — | ||
| Q2 25 | 0.4% | -5.6% | ||
| Q1 25 | 24.3% | 7.1% | ||
| Q4 24 | 26.8% | 11.7% | ||
| Q3 24 | 32.9% | 11.6% | ||
| Q2 24 | 23.7% | 13.3% |
| Q1 26 | $0.94 | — | ||
| Q4 25 | $0.78 | $0.24 | ||
| Q3 25 | $0.63 | — | ||
| Q2 25 | $0.01 | $-0.11 | ||
| Q1 25 | $0.65 | $0.14 | ||
| Q4 24 | $0.70 | $0.22 | ||
| Q3 24 | $1.18 | $0.21 | ||
| Q2 24 | $0.69 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $172.9M |
| Total DebtLower is stronger | $806.2M | $260.0M |
| Stockholders' EquityBook value | $3.9B | $2.0B |
| Total Assets | $27.1B | $2.5B |
| Debt / EquityLower = less leverage | 0.21× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $172.9M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.4B | $162.2M | ||
| Q1 25 | $1.1B | $140.7M | ||
| Q4 24 | $1.1B | $177.5M | ||
| Q3 24 | $1.3B | $187.5M | ||
| Q2 24 | $851.9M | $152.9M |
| Q1 26 | $806.2M | — | ||
| Q4 25 | $499.8M | $260.0M | ||
| Q3 25 | $558.9M | — | ||
| Q2 25 | $557.0M | $346.0M | ||
| Q1 25 | $433.3M | $330.0M | ||
| Q4 24 | $430.6M | $300.0M | ||
| Q3 24 | $433.2M | $300.0M | ||
| Q2 24 | $428.7M | $319.0M |
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.9B | $2.0B | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $3.8B | $1.9B | ||
| Q1 25 | $2.7B | $2.0B | ||
| Q4 24 | $2.7B | $2.1B | ||
| Q3 24 | $2.7B | $2.1B | ||
| Q2 24 | $2.4B | $2.1B |
| Q1 26 | $27.1B | — | ||
| Q4 25 | $26.8B | $2.5B | ||
| Q3 25 | $26.7B | — | ||
| Q2 25 | $26.6B | $2.6B | ||
| Q1 25 | $18.3B | $2.6B | ||
| Q4 24 | $18.0B | $2.7B | ||
| Q3 24 | $18.0B | $2.7B | ||
| Q2 24 | $17.5B | $2.7B |
| Q1 26 | 0.21× | — | ||
| Q4 25 | 0.13× | 0.13× | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.15× | 0.18× | ||
| Q1 25 | 0.16× | 0.16× | ||
| Q4 24 | 0.16× | 0.14× | ||
| Q3 24 | 0.16× | 0.14× | ||
| Q2 24 | 0.18× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RNST
| Net Interest Income | $223.6M | 82% |
| Noninterest Income | $50.3M | 18% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
